Data on the association of serum glypican-4 with future major adverse cardiovascular events and mortality in patients undergoing coronary angiography

Axel Muendlein; Eva Maria Brandtner; Andreas Leiherer; Kathrin Geiger; Christine Heinzle; Stella Gaenger; Peter Fraunberger; Arthur Mader; Christoph H Saely; Heinz Drexel

doi:10.1016/j.dib.2022.108142

Data on the association of serum glypican-4 with future major adverse cardiovascular events and mortality in patients undergoing coronary angiography

Data Brief. 2022 Apr 9:42:108142. doi: 10.1016/j.dib.2022.108142. eCollection 2022 Jun.

Authors

Axel Muendlein¹, Eva Maria Brandtner¹, Andreas Leiherer^{1

2

3}, Kathrin Geiger^{1

2}, Christine Heinzle^{1

2}, Stella Gaenger¹, Peter Fraunberger², Arthur Mader^{1

4}, Christoph H Saely^{1

3

4}, Heinz Drexel^{1

3

5

6}

Affiliations

¹ Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
² Medical Central Laboratories, Feldkirch, Austria.
³ Private University of the Principality of Liechtenstein, Triesen, Liechtenstein.
⁴ Department of Internal Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
⁵ Department of Medicine and Cardiology, Academic Teaching Hospital Bregenz, Bregenz, Austria.
⁶ Drexel University College of Medicine, Philadelphia, PA, USA.

Abstract

This data article is associated to the research article titled 'Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients' (Muendlein et al., 2022). The present article provides additional prospective data on the association of serum glypican-4 (GPC4) with the incidence of future major adverse cardiovascular events (MACE), vascular mortality, and overall mortality in a cohort of 760 coronary angiography patients. Serum GPC4 levels significantly differed between patients with or without an event during follow up. The results were confirmed in subgroup analyses with respect to age, sex, type 2 diabetes mellitus, obesity, the presence of significant coronary stenoses, and renal function, as well as medical treatment. That said, an interaction term between GPC4 and impaired renal function and between GPC4 and the use of beta blockers on the incidence of future fatal events reached statistical significance. In addition, C-statistics were performed showing an additional predictive value of categorized GPC4 to a basic risk model including traditional risk factors for overall mortality.

Keywords: Biomarker; Cardiovascular risk factors; GPC4; Glypican-4; MACE; Mortality.